PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...
SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of Good Manufacturing Practices (GMP), cutting-edge, induced pluripotent stem cell (iPSC) technologies, today announced the immediate ...
Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells (“iPSC”) derived from human ...
Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results